Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Payables (2020 - 2025)

Historic Payables for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $5.8 million.

  • Arcutis Biotherapeutics' Payables fell 7001.29% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year decrease of 7001.29%. This contributed to the annual value of $14.2 million for FY2024, which is 1857.91% up from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Payables of $5.8 million as of Q3 2025, which was down 7001.29% from $15.1 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Payables ranged from a high of $24.5 million in Q1 2025 and a low of $2.7 million during Q2 2021
  • Its 5-year average for Payables is $11.1 million, with a median of $12.0 million in 2023.
  • In the last 5 years, Arcutis Biotherapeutics' Payables soared by 29624.92% in 2022 and then tumbled by 7001.29% in 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' Payables (Quarter) stood at $7.4 million in 2021, then rose by 20.05% to $8.8 million in 2022, then surged by 35.86% to $12.0 million in 2023, then increased by 18.58% to $14.2 million in 2024, then tumbled by 59.25% to $5.8 million in 2025.
  • Its last three reported values are $5.8 million in Q3 2025, $15.1 million for Q2 2025, and $24.5 million during Q1 2025.